CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF844 (ImmuneEditome ID:284391)

1. Gene summary of enriched editing regions for ZNF844

check button Gene summary
Gene informationGene symbol

ZNF844

Gene ID

284391

GeneSynonyms-
GeneCytomap

19p13.2

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 844
GeneModificationdate20230329
UniprotIDA0A494C069;Q08AG5;F8VS19;F8WE48
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:12077866-12081067:+ENST00000439326.6ENSG00000223547.8ZNF844UTR3AluY,AluSx1,AluSz,AluSq2chr19:12077866-12081067:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF844


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:12077866-12081067:+BRCAEER5.9483e-06image
ENSG00000223547.8,ZNF844BRCAEAG5.5974e-06image
chr19:12077866-12081067:+COADEER5.7574e-04image
ENSG00000223547.8,ZNF844COADEAG5.7574e-04image
chr19:12077866-12081067:+HNSCEER2.5165e-02image
ENSG00000223547.8,ZNF844HNSCEAG2.5165e-02image
chr19:12077866-12081067:+KICHEER1.0127e-05image
ENSG00000223547.8,ZNF844KICHEAG9.6458e-06image
chr19:12077866-12081067:+KIRCEER6.3618e-09image
ENSG00000223547.8,ZNF844KIRCEAG7.1653e-09image
chr19:12077866-12081067:+KIRPEER4.2353e-02image
ENSG00000223547.8,ZNF844KIRPEAG4.1049e-02image
chr19:12077866-12081067:+LIHCEER1.3639e-02image
ENSG00000223547.8,ZNF844LIHCEAG1.3677e-02image
chr19:12077866-12081067:+THCAEER2.2130e-06image
ENSG00000223547.8,ZNF844THCAEAG1.9285e-06image
chr19:12077866-12081067:+UCECEER8.1165e-03image
ENSG00000223547.8,ZNF844UCECEAG7.4562e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000223547.8,ZNF844HNSCPathEAG8.2469e-032.5768e-03-0.3548image
chr19:12077866-12081067:+HNSCPathEER8.2469e-032.5768e-03-0.3548image
chr19:12077866-12081067:+THCAPathEER3.3864e-021.6817e-020.1069image
ENSG00000223547.8,ZNF844THCAPathEAG4.6284e-021.8216e-020.1056image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:12077866-12081067:+OVEER2.8696e-023.7133e-021.8548e+01image
ENSG00000223547.8,ZNF844OVEAG3.1410e-023.5980e-021.8924e+01image
chr19:12077866-12081067:+PRADEER2.8914e-024.3477e-021.7668e+07image
ENSG00000223547.8,ZNF844PRADEAG2.8914e-024.2463e-022.3147e+07image

Top

3. Enriched editing regions and immune related genes for ZNF844


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:12077866-12081067:+OVEERENSG00000223547,ZNF844-0.57853.2438e-205.6194e-19-0.4960imageNADAR;ELAVL1;HNRNPL;IGF2BP2;TAF15NAMast_cells_restingGSVA_HALLMARK_HYPOXIA
chr19:12077866-12081067:+OVEERENSG00000242615,CTC-359D24.3-0.52862.6502e-161.3051e-16-0.4653imageNNNANK_cells_restingGSVA_HALLMARK_APOPTOSIS
chr19:12077866-12081067:+OVEERENSG00000197044,ZNF441-0.48682.0337e-131.2865e-13-0.4215imageNADAR;ELAVL1;HNRNPL;IGF2BP2;TAF15NANK_cells_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:12077866-12081067:+OVEERENSG00000196646,ZNF136-0.46005.5643e-122.2614e-12-0.4012imageNADAR;ELAVL1;HNRNPL;IGF2BP2;TAF15NAT_cells_CD8GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:12077866-12081067:+OVEERENSG00000197647,ZNF433-0.45461.1451e-113.6016e-13-0.4144imageNELAVL1;IGF2BP2;TAF15NAMast_cells_restingGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr19:12077866-12081067:+OVEERENSG00000171291,ZNF439-0.45101.9748e-111.2244e-12-0.4057imageNELAVL1;IGF2BP2;TAF15NAMast_cells_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:12077866-12081067:+TGCTEERENSG00000132749,MTL5-0.48052.0299e-061.6034e-08-0.4627imageNADAR;ELAVL1;HNRNPL;IGF2BP2;TAF15NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
chr19:12077866-12081067:+TGCTEERENSG00000005801,ZNF195-0.45639.7890e-061.0560e-07-0.4383imageNADAR;ELAVL1;HNRNPL;IGF2BP2;TAF15NAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS
chr19:12077866-12081067:+TGCTEERENSG00000187140,FOXD3-0.39931.3351e-053.6930e-07-0.4210imageNELAVL1FOXD3T_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
chr19:12077866-12081067:+TGCTEERENSG00000124532,MRS2-0.45211.4796e-054.4694e-08-0.4497imageNADAR;ELAVL1;HNRNPL;IGF2BP2;TAF15NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for ZNF844


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:12077866-12081067:+
PCPGEERIRENSG00000105808.13chr7102593706:102594242:102594446:1025945590.36285.2742e-031.3426e-090.4843imageNADAR;HNRNPL;IGF2BP2;TAF15NAEosinophilsGSVA_HALLMARK_NOTCH_SIGNALING
ENSG00000223547.8,ZNF844
PCPGEAGIRENSG00000105808.13chr7102593706:102594242:102594446:1025945590.36334.6517e-031.2787e-090.4848imageNADAR;AIFM1;CSTF2T;DDX3X;FAM120A;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPL;HNRNPU;IGF2BP2;ILF3;LIN28B;LSM11;NONO;PRPF8;SMNDC1;SRSF1;TAF15;TARBP2;U2AF2NAEosinophilsGSVA_HALLMARK_NOTCH_SIGNALING
chr19:12077866-12081067:+
TGCTEERA5ENSG00000167555.9chr1952415123:52415344:52411371:52414368:52411371:524150390.27882.4885e-022.1135e-050.4076imageNADAR;ELAVL1;HNRNPL;IGF2BP2;TAF15NAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
chr19:12077866-12081067:+
TGCTEERA5ENSG00000143319.12chr1156727210:156727769:156728414:156728429:156728353:1567284290.36043.3285e-032.6197e-060.4046imageNADAR;ELAVL1;IGF2BP2;TAF15ISG20L2B_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr19:12077866-12081067:+
TGCTEERIRENSG00000162231.9chr1162798538:62798575:62800376:628004860.35484.2255e-031.4406e-060.4010imageNADAR;ELAVL1;HNRNPL;IGF2BP2;TAF15NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_GLYCOLYSIS
chr19:12077866-12081067:+
TGCTEERESENSG00000106682.10chr774189821:74189918:74190246:74190306:74194740:74194805-0.44144.2794e-043.3183e-07-0.4225imageNADAR;ELAVL1;HNRNPL;IGF2BP2;TAF15NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000223547.8,ZNF844
TGCTEAGESENSG00000135446.12chr1257751296:57751342:57751499:57751752:57752174:577522760.36381.5234e-032.1402e-060.4289imageNADAR;AIFM1;BCCIP;CSTF2T;DDX3X;DKC1;ELAVL1;FAM120A;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;MOV10;NONO;PRPF8;RBFOX2;SAFB2;SMNDC1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;U2AF2;UPF1CDK4T_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000223547.8,ZNF844
TGCTEAGMEXENSG00000104529.13chr8143590017:143590081:143590644:143590738:143592646:143592907:143597347:1435974150.37102.3686e-032.3637e-060.4033imageNADAR;AIFM1;BCCIP;CSTF2T;DDX3X;DHX9;DKC1;ELAVL1;FAM120A;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;MOV10;NONO;PRPF8;RBFOX2;RBM47;SAFB2;SMNDC1;SRSF1;SRSF9;TAF15;TARBP2;TARDBP;TRA2A;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000223547.8,ZNF844
TGCTEAGIRENSG00000160813.2chr7100435281:100435533:100435847:1004360640.39821.3008e-031.1622e-060.4042imageNAIFM1;BCCIP;CSTF2T;DDX3X;ELAVL1;FAM120A;FXR1;GTF2F1;HNRNPA1;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;MOV10;NONO;PRPF8;RBFOX2;SAFB2;SMNDC1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;U2AF2;UPF1NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000223547.8,ZNF844
TGCTEAGA3ENSG00000130751.5chr1947040443:47040550:47041024:47041125:47040977:470411250.28261.6901e-021.8712e-060.4580imageNADAR;CSTF2T;DDX3X;DHX9;DKC1;FAM120A;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;LIN28B;LSM11;MOV10;PRPF8;RBFOX2;SAFB2;SMNDC1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;U2AF2;UPF1NAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS

More results



Top

5. Enriched editing regions and immune infiltration for ZNF844


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:12077866-12081067:+ACCEERDendritic_cells_activated3.8503e-040.4436image
ENSG00000223547.8,ZNF844ACCEAGDendritic_cells_activated4.0518e-040.4421image
chr19:12077866-12081067:+BLCAEERT_cells_regulatory_(Tregs)8.1933e-03-0.1597image
ENSG00000223547.8,ZNF844BLCAEAGT_cells_regulatory_(Tregs)8.1933e-03-0.1597image
chr19:12077866-12081067:+BRCAEERT_cells_CD4_memory_activated4.2341e-080.1711image
ENSG00000223547.8,ZNF844BRCAEAGT_cells_CD4_memory_activated5.1032e-080.1700image
chr19:12077866-12081067:+CHOLEERB_cells_naive4.2432e-020.4174image
ENSG00000223547.8,ZNF844CHOLEAGB_cells_naive4.2432e-020.4174image
chr19:12077866-12081067:+COADEERT_cells_gamma_delta1.2235e-020.2159image
ENSG00000223547.8,ZNF844COADEAGT_cells_gamma_delta1.2235e-020.2159image
ENSG00000223547.8,ZNF844DLBCEAGT_cells_CD4_memory_activated2.2220e-020.4465image
chr19:12077866-12081067:+ESCAEEREosinophils3.3270e-020.2567image
ENSG00000223547.8,ZNF844ESCAEAGEosinophils3.6234e-020.2526image
chr19:12077866-12081067:+GBMEERMonocytes1.0184e-020.2020image
ENSG00000223547.8,ZNF844GBMEAGMonocytes1.0199e-020.2020image
chr19:12077866-12081067:+HNSCEERPlasma_cells2.8614e-02-0.2433image
ENSG00000223547.8,ZNF844HNSCEAGPlasma_cells2.8614e-02-0.2433image
chr19:12077866-12081067:+KICHEERB_cells_naive1.9161e-02-0.2921image
ENSG00000223547.8,ZNF844KICHEAGB_cells_naive1.8889e-02-0.2928image
chr19:12077866-12081067:+KIRCEERPlasma_cells5.0216e-060.2395image
ENSG00000223547.8,ZNF844KIRCEAGPlasma_cells5.1748e-060.2392image
chr19:12077866-12081067:+KIRPEERMacrophages_M22.8963e-03-0.1865image
ENSG00000223547.8,ZNF844KIRPEAGMacrophages_M22.8290e-03-0.1870image
chr19:12077866-12081067:+LGGEEREosinophils3.2929e-040.1560image
ENSG00000223547.8,ZNF844LGGEAGEosinophils3.3216e-040.1559image
chr19:12077866-12081067:+LIHCEERMast_cells_resting2.4484e-030.1984image
ENSG00000223547.8,ZNF844LIHCEAGMast_cells_resting2.4454e-030.1984image
chr19:12077866-12081067:+LUADEERT_cells_CD4_memory_activated6.2611e-040.1929image
ENSG00000223547.8,ZNF844LUADEAGT_cells_CD4_memory_activated6.2613e-040.1929image
chr19:12077866-12081067:+LUSCEERT_cells_CD81.6739e-02-0.1844image
ENSG00000223547.8,ZNF844LUSCEAGT_cells_CD81.6739e-02-0.1844image
chr19:12077866-12081067:+OVEERT_cells_CD85.1671e-050.2382image
ENSG00000223547.8,ZNF844OVEAGT_cells_CD85.3211e-050.2378image
chr19:12077866-12081067:+PAADEERT_cells_CD4_naive3.4578e-040.3308image
ENSG00000223547.8,ZNF844PAADEAGT_cells_CD4_naive3.4578e-040.3308image
chr19:12077866-12081067:+PCPGEERT_cells_CD4_memory_activated5.4775e-030.2320image
ENSG00000223547.8,ZNF844PCPGEAGT_cells_CD4_memory_activated5.5210e-030.2317image
chr19:12077866-12081067:+PRADEERT_cells_follicular_helper3.2346e-03-0.1321image
ENSG00000223547.8,ZNF844PRADEAGT_cells_follicular_helper3.1246e-03-0.1326image
chr19:12077866-12081067:+READEERMast_cells_activated1.5696e-040.4726image
ENSG00000223547.8,ZNF844READEAGMast_cells_activated1.5696e-040.4726image
chr19:12077866-12081067:+SARCEERT_cells_CD4_memory_activated2.9044e-020.1489image
ENSG00000223547.8,ZNF844SARCEAGT_cells_CD4_memory_activated2.9167e-020.1484image
chr19:12077866-12081067:+STADEERT_cells_CD87.2454e-030.1814image
ENSG00000223547.8,ZNF844STADEAGT_cells_CD87.6339e-030.1802image
chr19:12077866-12081067:+TGCTEERT_cells_CD4_memory_resting6.5465e-030.2330image
ENSG00000223547.8,ZNF844TGCTEAGT_cells_CD4_memory_resting6.5465e-030.2330image
chr19:12077866-12081067:+THCAEERDendritic_cells_activated2.8041e-050.1860image
ENSG00000223547.8,ZNF844THCAEAGDendritic_cells_activated1.3093e-040.1700image
chr19:12077866-12081067:+THYMEERT_cells_gamma_delta1.7636e-030.3031image
ENSG00000223547.8,ZNF844THYMEAGT_cells_gamma_delta1.7663e-030.3030image
chr19:12077866-12081067:+UCECEERT_cells_CD4_memory_resting6.0166e-030.2130image
ENSG00000223547.8,ZNF844UCECEAGT_cells_CD4_memory_resting1.1745e-020.1946image


Top

6. Enriched editing regions and immune gene sets for ZNF844


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr19:12077866-12081067:+BRCAEER1.9950e-02image3.7377e-050.1291image
ENSG00000223547.8,ZNF844BRCAEAG2.3656e-02image3.5596e-050.1294image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr19:12077866-12081067:+BLCAEER5.7582e-030.16678.4880e-030.15905.9415e-030.16612.0845e-030.1855image
ENSG00000223547.8,ZNF844BLCAEAG5.7582e-030.16678.4880e-030.15905.9415e-030.16612.0845e-030.1855image
chr19:12077866-12081067:+BRCAEER7.5745e-090.18024.5461e-070.15763.1175e-030.09271.9552e-070.1625image
ENSG00000223547.8,ZNF844BRCAEAG9.2071e-090.17924.9180e-070.15723.4954e-030.09161.9739e-070.1625image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000223547.8,ZNF844ACCGSVA_HALLMARK_GLYCOLYSISEAG1.7955e-050.5232image
chr19:12077866-12081067:+ACCGSVA_HALLMARK_GLYCOLYSISEER1.7777e-050.5234image
chr19:12077866-12081067:+BLCAGSVA_HALLMARK_MTORC1_SIGNALINGEER1.2651e-040.2299image
ENSG00000223547.8,ZNF844BLCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.2651e-040.2299image
chr19:12077866-12081067:+BRCAGSVA_HALLMARK_COMPLEMENTEER3.7914e-130.2254image
ENSG00000223547.8,ZNF844BRCAGSVA_HALLMARK_COMPLEMENTEAG3.8653e-130.2253image
chr19:12077866-12081067:+CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.7483e-030.2742image
ENSG00000223547.8,ZNF844CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.7483e-030.2742image
ENSG00000223547.8,ZNF844CHOLGSVA_HALLMARK_ANDROGEN_RESPONSEEAG6.0654e-030.5434image
chr19:12077866-12081067:+CHOLGSVA_HALLMARK_ANDROGEN_RESPONSEEER6.0654e-030.5434image
chr19:12077866-12081067:+COADGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.2274e-030.2620image
ENSG00000223547.8,ZNF844COADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.2274e-030.2620image
chr19:12077866-12081067:+GBMGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.0472e-020.1825image
ENSG00000223547.8,ZNF844GBMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.0459e-020.1826image
chr19:12077866-12081067:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.6690e-020.2326image
ENSG00000223547.8,ZNF844HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.6690e-020.2326image
ENSG00000223547.8,ZNF844KICHGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG9.0910e-030.3236image
chr19:12077866-12081067:+KICHGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER8.2149e-030.3277image
ENSG00000223547.8,ZNF844KIRCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG1.0203e-040.2048image
chr19:12077866-12081067:+KIRCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER9.1019e-050.2062image
chr19:12077866-12081067:+KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.0863e-020.1599image
ENSG00000223547.8,ZNF844KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.0995e-020.1596image
ENSG00000223547.8,ZNF844LGGGSVA_HALLMARK_DNA_REPAIREAG4.1522e-07-0.2186image
chr19:12077866-12081067:+LGGGSVA_HALLMARK_DNA_REPAIREER4.2467e-07-0.2184image
ENSG00000223547.8,ZNF844LIHCGSVA_HALLMARK_GLYCOLYSISEAG1.7669e-020.1560image
chr19:12077866-12081067:+LIHCGSVA_HALLMARK_GLYCOLYSISEER1.7710e-020.1559image
chr19:12077866-12081067:+LUADGSVA_HALLMARK_MITOTIC_SPINDLEEER3.1471e-040.2030image
ENSG00000223547.8,ZNF844LUADGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.1444e-040.2030image
ENSG00000223547.8,ZNF844LUSCGSVA_HALLMARK_MYC_TARGETS_V2EAG2.9376e-020.1681image
chr19:12077866-12081067:+LUSCGSVA_HALLMARK_MYC_TARGETS_V2EER2.9376e-020.1681image
chr19:12077866-12081067:+MESOGSVA_HALLMARK_ANGIOGENESISEER2.3682e-030.3822image
ENSG00000223547.8,ZNF844MESOGSVA_HALLMARK_ANGIOGENESISEAG2.3682e-030.3822image
ENSG00000223547.8,ZNF844OVGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG8.0092e-100.3549image
chr19:12077866-12081067:+OVGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER7.4197e-100.3555image
chr19:12077866-12081067:+PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.4983e-03-0.2953image
ENSG00000223547.8,ZNF844PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.4983e-03-0.2953image
ENSG00000223547.8,ZNF844PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.7018e-040.3104image
chr19:12077866-12081067:+PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER1.7387e-040.3100image
ENSG00000223547.8,ZNF844PRADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG7.1921e-040.1515image
chr19:12077866-12081067:+PRADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER7.3802e-040.1512image
ENSG00000223547.8,ZNF844READGSVA_HALLMARK_GLYCOLYSISEAG7.6984e-040.4259image
chr19:12077866-12081067:+READGSVA_HALLMARK_GLYCOLYSISEER7.6984e-040.4259image
ENSG00000223547.8,ZNF844SARCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.2006e-030.2190image
chr19:12077866-12081067:+SARCGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.1225e-030.2207image
ENSG00000223547.8,ZNF844SKCMGSVA_HALLMARK_UV_RESPONSE_UPEAG7.3658e-030.1655image
chr19:12077866-12081067:+SKCMGSVA_HALLMARK_UV_RESPONSE_UPEER7.3824e-030.1655image
chr19:12077866-12081067:+STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.0951e-050.2930image
ENSG00000223547.8,ZNF844STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.2186e-050.2915image
chr19:12077866-12081067:+TGCTGSVA_HALLMARK_GLYCOLYSISEER1.2636e-04-0.3240image
ENSG00000223547.8,ZNF844TGCTGSVA_HALLMARK_GLYCOLYSISEAG1.2636e-04-0.3240image
chr19:12077866-12081067:+THCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER6.2718e-110.2866image
ENSG00000223547.8,ZNF844THCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.0201e-090.2684image
chr19:12077866-12081067:+UCECGSVA_HALLMARK_DNA_REPAIREER5.0361e-03-0.2174image
ENSG00000223547.8,ZNF844UCECGSVA_HALLMARK_DNA_REPAIREAG5.8245e-03-0.2125image
ENSG00000223547.8,ZNF844UCSGSVA_HALLMARK_P53_PATHWAYEAG2.8255e-020.3104image
chr19:12077866-12081067:+UCSGSVA_HALLMARK_P53_PATHWAYEER2.7879e-020.3111image
chr19:12077866-12081067:+UVMGSVA_HALLMARK_UV_RESPONSE_UPEER6.0050e-030.4078image
ENSG00000223547.8,ZNF844UVMGSVA_HALLMARK_UV_RESPONSE_UPEAG6.0050e-030.4078image


Top

7. Enriched editing regions and drugs for ZNF844


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:12077866-12081067:+BLCACisplatinEER5.3201e-06-0.2715image
ENSG00000223547.8,ZNF844BLCACisplatinEAG5.3201e-06-0.2715image
chr19:12077866-12081067:+BRCACGP.082996EER8.1713e-10-0.1913image
ENSG00000223547.8,ZNF844BRCACGP.082996EAG8.4578e-10-0.1912image
chr19:12077866-12081067:+CESCAICAREER7.8544e-03-0.2522image
ENSG00000223547.8,ZNF844CESCAICAREAG7.8544e-03-0.2522image
ENSG00000223547.8,ZNF844CHOLCyclopamineEAG5.0693e-030.5530image
chr19:12077866-12081067:+CHOLCyclopamineEER5.0693e-030.5530image
chr19:12077866-12081067:+COADAICAREER1.0549e-02-0.2203image
ENSG00000223547.8,ZNF844COADAICAREAG1.0549e-02-0.2203image
chr19:12077866-12081067:+ESCAEHT.1864EER1.8158e-020.2837image
ENSG00000223547.8,ZNF844ESCAEHT.1864EAG1.5049e-020.2916image
chr19:12077866-12081067:+GBMCGP.082996EER1.4443e-03-0.2490image
ENSG00000223547.8,ZNF844GBMCGP.082996EAG1.4580e-03-0.2488image
chr19:12077866-12081067:+HNSCDocetaxelEER4.0651e-02-0.2280image
ENSG00000223547.8,ZNF844HNSCDocetaxelEAG4.0651e-02-0.2280image
ENSG00000223547.8,ZNF844KICHCCT018159EAG9.4552e-03-0.3220image
chr19:12077866-12081067:+KICHCCT018159EER9.3971e-03-0.3223image
ENSG00000223547.8,ZNF844KIRCAZD6244EAG6.3246e-08-0.2822image
chr19:12077866-12081067:+KIRCAZD6244EER6.0787e-08-0.2826image
ENSG00000223547.8,ZNF844KIRPElesclomolEAG2.9595e-030.1861image
chr19:12077866-12081067:+KIRPElesclomolEER2.8521e-030.1868image
ENSG00000223547.8,ZNF844LAMLBryostatin.1EAG4.0539e-03-0.4499image
ENSG00000223547.8,ZNF844LGGAZD8055EAG6.5178e-060.1952image
chr19:12077866-12081067:+LGGAZD8055EER6.4651e-060.1952image
ENSG00000223547.8,ZNF844LIHCAZD.2281EAG2.0033e-020.1540image
chr19:12077866-12081067:+LIHCAZD.2281EER2.0036e-020.1540image
ENSG00000223547.8,ZNF844LUADDoxorubicinEAG2.9956e-04-0.2037image
chr19:12077866-12081067:+LUADDoxorubicinEER2.9970e-04-0.2037image
ENSG00000223547.8,ZNF844LUSCBosutinibEAG1.6021e-03-0.2416image
chr19:12077866-12081067:+LUSCBosutinibEER1.6021e-03-0.2416image
chr19:12077866-12081067:+MESOEHT.1864EER6.6364e-040.4239image
ENSG00000223547.8,ZNF844MESOEHT.1864EAG6.6364e-040.4239image
ENSG00000223547.8,ZNF844OVBMS.536924EAG3.2163e-05-0.2445image
chr19:12077866-12081067:+OVBMS.536924EER2.8618e-05-0.2460image
chr19:12077866-12081067:+PAADABT.263EER3.7832e-020.1992image
ENSG00000223547.8,ZNF844PAADABT.263EAG3.7832e-020.1992image
ENSG00000223547.8,ZNF844PCPGBI.2536EAG2.2882e-050.3473image
chr19:12077866-12081067:+PCPGBI.2536EER2.3285e-050.3470image
ENSG00000223547.8,ZNF844PRADGW.441756EAG7.4950e-050.1770image
chr19:12077866-12081067:+PRADGW.441756EER7.6579e-050.1768image
ENSG00000223547.8,ZNF844READErlotinibEAG1.1605e-020.3293image
chr19:12077866-12081067:+READErlotinibEER1.1605e-020.3293image
ENSG00000223547.8,ZNF844SARCCMKEAG5.5296e-040.2331image
chr19:12077866-12081067:+SARCCMKEER5.6400e-040.2333image
chr19:12077866-12081067:+SKCMJNK.9LEER1.1554e-03-0.2001image
ENSG00000223547.8,ZNF844SKCMJNK.9LEAG1.1543e-03-0.2001image
chr19:12077866-12081067:+STADBAY.61.3606EER1.4117e-030.2149image
ENSG00000223547.8,ZNF844STADBAY.61.3606EAG1.5020e-030.2137image
chr19:12077866-12081067:+TGCTAKT.inhibitor.VIIIEER8.4475e-06-0.3728image
ENSG00000223547.8,ZNF844TGCTAKT.inhibitor.VIIIEAG8.4475e-06-0.3728image
ENSG00000223547.8,ZNF844THCAAZD.0530EAG2.7520e-10-0.2772image
chr19:12077866-12081067:+THCAAZD.0530EER3.2134e-10-0.2761image
chr19:12077866-12081067:+THYMAUY922EER9.9239e-050.3724image
ENSG00000223547.8,ZNF844THYMAUY922EAG9.9857e-050.3722image
chr19:12077866-12081067:+UCECEHT.1864EER5.9405e-030.2133image
ENSG00000223547.8,ZNF844UCECEHT.1864EAG6.0341e-030.2117image
ENSG00000223547.8,ZNF844UCSMG.132EAG3.3089e-03-0.4075image
chr19:12077866-12081067:+UCSMG.132EER3.2955e-03-0.4077image
chr19:12077866-12081067:+UVMA.443654EER9.5675e-05-0.5540image
ENSG00000223547.8,ZNF844UVMA.443654EAG9.5675e-05-0.5540image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType